Variables | cohort (n = 1579) | Normal group (n = 369) | High group (n = 1210) | P value |
---|---|---|---|---|
Age (years) | 49.3 ± 14.6 | 45.8 ± 13.7 | 50.3 ± 14.7 | < 0.001 |
Male (%) | 874 (55.4) | 276 (74.8) | 598 (49.4) | < 0.001 |
CCI | 3.87 ± 1.66 | 3.59 ± 1.58 | 3.95 ± 1.68 | < 0.001 |
Diabetes (%) | 286 (18.1) | 64 (17.3) | 222 (18.3) | 0.700 |
Hypertension (%) | 1014 (64.2) | 244 (66.1) | 770 (63.6) | 0.420 |
Hyperlipidemia (%) | 256 (16.2) | 46 (12.5) | 210 (17.4) | 0.029 |
Gastrointestinal bleeding (%) | 41 (2.6) | 10 (2.7) | 31 (2.6) | 0.853 |
Current smoking (%) | 47 (3.0) | 6 (1.6) | 41 (3.4) | 0.113 |
ACEI/ARB use (%) | 518 (32.8) | 114 (30.9) | 404 (33.4) | 0.410 |
Calcium antagonist use (%) | 1141 (72.3) | 272 (73.7) | 869 (1.8) | 0.507 |
β-blocker use (%) | 505 (32.0) | 122 (33.1) | 383 (31.7) | 0.611 |
Diuretic use (%) | 94 (6.0) | 20 (5.4) | 74 (6.1) | 0.707 |
Statin use (%) | 157 (9.9) | 26 (7.0) | 131 (10.8) | 0.037 |
BMI (kg/m2) | 22.1 ± 3.6 | 22.3 ± 4.5 | 22.0 ± 3.3 | 0.305 |
Ejection fraction (%) | 60.0 ± 5.9 | 59.8 ± 6.6 | 60.0 ± 5.7 | 0.820 |
eGFR (ml/min/1.73 m2) | 5.63 (4.38–8.47) | 5.81 (4.31–8.93) | 5.50 (4.01–8.64) | 0.367 |
Hemoglobin (g/dL) | 8.6 ± 2.0 | 8.6 ± 2.1 | 8.6 ± 2.0 | 0.873 |
Albumin (g/dL) | 3.5 ± 0.5 | 3.5 ± 0.5 | 3.4 ± 0.5 | 0.059 |
AST (IU/L) | 18 (14–23) | 19 (13–25) | 18 (14–23) | 0.086 |
ALT (IU/L) | 13 (8–20) | 36 (27–56) | 8 (5–11) | < 0.001 |
Bilirubin (mg/dL) | 0.30 (0.22–0.41) | 0.33 (0.27–0.40) | 0.30 (0.21–0.41) | 0.565 |
Cholesterol (mg/dL) | 159 ± 60 | 156 ± 55 | 160 ± 61 | 0.361 |
Triglyceride (mg/dL) | 132 ± 97 | 126 ± 90 | 133 ± 98 | 0.198 |
HDL (mg/dL) | 45.4 ± 16.3 | 44.7 ± 17.1 | 45.6 ± 16.1 | 0.432 |
LDL (mg/dL) | 99.0 ± 38.8 | 95.1 ± 37.0 | 100.2 ± 39.3 | 0.038 |
hs-CRP (mg/L) | 4.03 (1.97–11.04) | 2.25 (0.85–19.5) | 4.25 (2.04–14.20) | 0.209 |
NT-pro-BNP (pg/mL) | 2017 (800–6545) | 771 (412–4835) | 2375 (840–5760) | 0.824 |
24-h urine output (mL) | 851 ± 534 | 890 ± 589 | 839 ± 527 | 0.131 |